XML 57 R46.htm IDEA: XBRL DOCUMENT
v3.22.2.2

License Agreements - Merus (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 70 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Jan. 31, 2022 item | Jan. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2016 USD ($) item $ / shares | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2016 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) | Dec. 31, 2021 USD ($)
License Agreements |  |  |  |  |  |  |  |  |  |
Unrealized gain (loss) on long term investments |  |  |  | $ (660) | $ (27,450) | $ (72,142) | $ (28,394) |  |  |
Merus |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Fair market value of our long term investments |  |  |  | $ 71,100 |  | $ 71,100 |  |  | $ 71,100 | $ 112,900
Ownership percentage (as a percent) |  |  |  | 8.00% |  | 8.00% |  |  | 8.00% |
Unrealized gain (loss) on long term investments |  |  |  | $ (9,300) | $ 3,300 | $ (41,800) | $ 13,300 |  |  |
Merus | IPO |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Per share price (In USD per share) | $ / shares |  | $ 24.75 |  |  |  |  |  |  |  |
Common shares purchased (in shares) | shares |  | 350,000 |  |  |  |  |  |  |  |
Number of shares in underwritten public offering (in shares) | shares |  | 4,848,485 |  |  |  |  |  |  |  |
Value of shares acquired |  | $ 8,700 |  |  |  |  |  |  |  |
Merus |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Number of independent programs | item |  |  | 10 |  |  |  |  |  |  |
Number of additional preclinical discovery programs | item | 10 |  |  |  |  |  |  |  |  |
Number of programs under the resulting products are co-funded for development | item | 2 |  |  |  |  |  |  |  |  |
Associated future global development costs , if elected to co-develop (as a percent) | 35.00% |  |  |  |  |  |  |  |  |
Milestone payment made under license agreement |  |  |  |  |  |  |  |  | $ 3,000 |
Merus | UNITED STATES |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Profit sharing (as a percent) |  |  |  |  |  |  |  |  | 50.00% |
Percentage of profit (losses) |  |  |  |  |  |  |  |  | 50.00% |
Merus | Minimum |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  |  | 6.00% |
Merus | Minimum | Non-US |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  |  | 6.00% |
Merus | Maximum |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  |  | 10.00% |
Merus | Maximum | UNITED STATES |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  |  | 4.00% |
Merus | Maximum | Non-US |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  |  | 10.00% |
Merus | Maximum | Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  |  | 100,000 |  | 100,000 |  |  | $ 100,000 |
Merus | Maximum | Commercialization Milestones |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  |  | $ 250,000 |  | $ 250,000 |  |  | $ 250,000 |
Stock purchase agreement | Merus |  |  |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |  |  |
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares |  |  |  |  |  |  |  | 3,200,000 |  |
Purchase price of common stock |  |  | $ 80,000 |  |  |  |  | $ 80,000 |  |
Per share price (In USD per share) | $ / shares |  |  | $ 25.00 |  |  |  |  | $ 25.00 |  |

X
- Definition Represents the percentage of profits and losses shared under the collaboration agreement. + References No definition available. + Details
Name: | incy_CollaborationAgreementProfitSharingPercentage
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the aggregate shares purchased of investments accounted for under the equity method of accounting. + References No definition available. + Details
Name: | incy_EquityMethodInvestmentSharesPurchased
Namespace Prefix: | incy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the maximum number of independent programs encompassed under the collaboration agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMaximumNumberOfIndependentPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of the milestone payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of additional preclinical discovery programs. + References No definition available. + Details
Name: | incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs in which the resulting products are co-funded for development. + References No definition available. + Details
Name: | incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. + References No definition available. + Details
Name: | incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of profits (losses). + References No definition available. + Details
Name: | incy_PercentageOfProfitsLosses
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. + References No definition available. + Details
Name: | incy_PercentageOfRoyaltyRatePayments
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the purchase of common stock under Stock Purchase Agreement. + References No definition available. + Details
Name: | incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
Namespace Prefix: | incy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentQuotedMarketValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |